AI-driven autonomous robotics for cell therapy manufacturing, delivered in partnership with Made Scientific
.png?width=1024&height=123&name=streamline_bio_logo-1024x123%20(1).png){kind=logo}
Early Adopter Program for Therapeutic Developers
Made Scientific and Streamline Bio are building an integrated CDMO + automation offering for therapeutic developers, with the Early Adopter Program focused on early to late-phase CAR-T programs.
- Why CAR-T: complex, multi-step workflows can amplify variability and operational risk
- Where we are today: AI-driven precision robotics validated in a live manufacturing setting
- What’s next: progressing toward GMP integration within Made Scientific cleanrooms
- Program intent: reduce manual handling, improve execution consistency, and strengthen data capture for documentation and change control
Where Streamline Bio Automation Fits in Cell Therapy Manufacturing
Initial focus: CAR-T workflows
Streamline Bio’s modular robotics are designed to integrate into existing infrastructure and support diverse equipment and protocols with minimal disruption.
- Standardize labor-intensive steps to reduce execution variability
- Improve traceability to support deviations, investigations, and comparability
- Enable repeatable workflows designed for scale-up and multi-suite deployment
What customers can expect:
Automation designed for existing cleanrooms
CDMO execution aligned to development and scale
Data capture that supports GMP expectations
Designed for repeatability across suites and shifts
%20expanded.png?height=2000&name=StreamlineBio_005%20(1)%20expanded.png)
Engagement Models Built for Speed and Control
Choose the engagement model that matches your internal capabilities and the level of hands-on collaboration you want during automation evaluation and deployment:
- Fee-for-service execution
Best for defined studies with clear deliverables and timelines. - Dedicated team execution
Best for sustained development support, rapid iteration, and parallel workstreams. - Hybrid client-in-plant operations
Best for joint execution, on-site knowledge transfer, and shared process ownership. - Early Adopter collaboration
Best for teams co-developing automation workflows and extending capability across unit operations.
Why Partner with Made Scientific + Streamline Bio
Streamline Bio automation, deployed with Made Scientific
- AI-driven autonomous, modular robotics designed for cell therapy manufacturing
- Validated in a live manufacturing setting at Made Scientific (Princeton, NJ) and progressing toward GMP integration
- Designed to integrate with common cell therapy equipment (CliniMACS Prodigy®, G-Rex®, LOVO®)
- Supports reduced manual handling and improved execution consistency
Integrated CDMO services, automation-ready by design
- GMP-ready execution model for evaluation, integration planning, and tech transfer considerations
- Structured documentation practices aligned with GMP expectations
- Flexible engagement models to match program timeline and internal capabilities
- Designed to support comparability and continuous improvement as workflows mature
Made Scientific and Streamline Bio Announce Collaboration to Accelerate AI-Driven Robotic Manufacturing for Cell Therapies
In October 2025, Made Scientific and Streamline Bio announced successful initial validation of Streamline Bio’s AI-driven precision robotics in a live cell therapy production environment at Made Scientific’s Princeton facility. Learn how the collaboration is advancing toward GMP integration and early adopter programs.
Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing
In February 2026, Made Scientific announced as exclusive cell therapy CDMO partner for Streamline Bio's platform, accelerating development of autonomous manufacturing workflows in GMP cleanroom environments.